MorphoSys AG
DelistedCIK 1340243fmd_09WA1MR9APC54XVCXV0ASF8K2WManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Dec 31, 2023, 8 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 50 | 67 | 76 | 72 | 328 | 180 | 278 | 238 |
| Cost of revenue | 0 | 0 | 2 | 12 | 9 | 32 | 49 | 58 |
| Gross profit | 50 | 67 | 75 | 60 | 319 | 147 | 230 | 180 |
| Research and development | 94 | 113 | 106 | 108 | 139 | 225 | 298 | 284 |
| Selling, general and administrative | 16 | 21 | 28 | 59 | 159 | 200 | 153 | 147 |
| Operating income | (60) | (68) | (59) | (108) | 18 | (508) | (221) | (252) |
| Interest expense | 1 | 2 | 1 | 2 | 96 | 181 | 166 | 142 |
| Income before taxes | (60) | (69) | (60) | (107) | 22 | – | – | – |
| Income tax expense | 1 | 1 | (4) | (4) | (75) | (77) | 169 | (1) |
| Net income from continuing operations | (60) | (70) | (56) | (103) | 98 | – | – | – |
| Net income | (60) | (70) | (56) | (103) | 98 | (514) | (151) | (190) |